MX2019010732A - Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. - Google Patents
Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina.Info
- Publication number
- MX2019010732A MX2019010732A MX2019010732A MX2019010732A MX2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A MX 2019010732 A MX2019010732 A MX 2019010732A
- Authority
- MX
- Mexico
- Prior art keywords
- catecholamine
- cst
- tumors
- cushing
- bind
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 150000003943 catecholamines Chemical class 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 3
- 230000003248 secreting effect Effects 0.000 title abstract 2
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 5
- 108090000079 Glucocorticoid Receptors Proteins 0.000 abstract 5
- 102000003998 progesterone receptors Human genes 0.000 abstract 4
- 108090000468 progesterone receptors Proteins 0.000 abstract 4
- 208000014311 Cushing syndrome Diseases 0.000 abstract 3
- 201000011519 neuroendocrine tumor Diseases 0.000 abstract 3
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 2
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000011349 peptide receptor radionuclide therapy Methods 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469296P | 2017-03-09 | 2017-03-09 | |
| PCT/US2018/021592 WO2018165460A1 (en) | 2017-03-09 | 2018-03-08 | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010732A true MX2019010732A (es) | 2019-11-01 |
Family
ID=63446773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010732A MX2019010732A (es) | 2017-03-09 | 2018-03-08 | Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11045482B2 (https=) |
| EP (1) | EP3592358A4 (https=) |
| JP (3) | JP7564620B2 (https=) |
| CN (1) | CN110475558A (https=) |
| AU (1) | AU2018230429B2 (https=) |
| CA (1) | CA3053806A1 (https=) |
| MX (1) | MX2019010732A (https=) |
| WO (1) | WO2018165460A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202105746TA (en) | 2018-12-20 | 2021-07-29 | Corcept Therapeutics Inc | Methods for imaging and treatment of somatostatin-receptor positive tumors |
| JP2021079146A (ja) * | 2021-02-22 | 2021-05-27 | 株式会社三洋物産 | 遊技機 |
| JP7315071B2 (ja) * | 2021-03-03 | 2023-07-26 | 株式会社三洋物産 | 遊技機 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606736D0 (en) | 1996-02-19 | 1996-06-05 | Shire International Licensing | Therapeutic method |
| CA2246791A1 (en) | 1998-09-01 | 2000-03-01 | Alison Buchan | Treatment of endothelium with somatostatin analogues |
| CA2325169A1 (en) | 1999-12-03 | 2001-06-03 | Ndsu Research Foundation | Somatostatins and method |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| DE60232956D1 (de) | 2001-03-23 | 2009-08-27 | Corcept Therapeutics Inc | Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten |
| US7189856B2 (en) | 2001-12-28 | 2007-03-13 | Gideon Shapiro | Non-peptide somatostatin receptor ligands |
| CA2558899C (en) | 2004-03-09 | 2013-02-05 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
| US20100178663A1 (en) * | 2007-05-15 | 2010-07-15 | Waters Technologies Corporation | Apparatus And Methods For The Detection Of Plasma Metanephrines |
| US20100261693A1 (en) | 2007-10-17 | 2010-10-14 | Ulmann Andre | Method for treating cushing's syndrome |
| ES2351569B8 (es) | 2009-05-07 | 2012-06-20 | Bcn Peptides S.A. | Ligandos peptídicos de receptores de somatostatina. |
| JP5637568B2 (ja) | 2009-05-12 | 2014-12-10 | コーセプト セラピューティクス， インコーポレイテッド | 固体形態および調製のためのプロセス |
| ES2999020T3 (en) * | 2010-02-05 | 2025-02-24 | Phosphagenics Ltd | Carrier comprising non-neutralised tocopheryl phosphate |
| MY161170A (en) | 2011-03-18 | 2017-04-14 | Corcept Therapeutics Inc | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
| WO2013039916A1 (en) * | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PL3848027T3 (pl) | 2013-11-25 | 2023-07-24 | Corcept Therapeutics Incorporated | Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego |
| AU2016226451B2 (en) * | 2015-03-02 | 2019-12-19 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors |
| US9943526B2 (en) * | 2015-04-21 | 2018-04-17 | Corcept Therapeutics, Inc. | Optimizing mifepristone levels for cushing's patients |
-
2018
- 2018-03-08 AU AU2018230429A patent/AU2018230429B2/en active Active
- 2018-03-08 JP JP2019548370A patent/JP7564620B2/ja active Active
- 2018-03-08 CN CN201880015928.3A patent/CN110475558A/zh active Pending
- 2018-03-08 CA CA3053806A patent/CA3053806A1/en active Pending
- 2018-03-08 MX MX2019010732A patent/MX2019010732A/es unknown
- 2018-03-08 WO PCT/US2018/021592 patent/WO2018165460A1/en not_active Ceased
- 2018-03-08 US US15/915,284 patent/US11045482B2/en active Active
- 2018-03-08 EP EP18763240.1A patent/EP3592358A4/en active Pending
-
2022
- 2022-04-21 JP JP2022070027A patent/JP2022090003A/ja not_active Withdrawn
-
2024
- 2024-03-28 JP JP2024053332A patent/JP2024074854A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020510011A (ja) | 2020-04-02 |
| AU2018230429A1 (en) | 2019-09-05 |
| JP2024074854A (ja) | 2024-05-31 |
| JP7564620B2 (ja) | 2024-10-09 |
| JP2022090003A (ja) | 2022-06-16 |
| EP3592358A4 (en) | 2020-12-16 |
| AU2018230429B2 (en) | 2023-06-15 |
| EP3592358A1 (en) | 2020-01-15 |
| WO2018165460A1 (en) | 2018-09-13 |
| US20180256604A1 (en) | 2018-09-13 |
| CN110475558A (zh) | 2019-11-19 |
| US11045482B2 (en) | 2021-06-29 |
| CA3053806A1 (en) | 2018-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009011540A (es) | Tratamiento de desordenes de movimiento con el uso combinado de toxina botulinica y estimulacion del musculo. | |
| ZA202006481B (en) | Anti-msr1 antibodies and methods of use thereof | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| WO2016187220A3 (en) | Anti-ror1 antibodies | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| GB2454118A (en) | Hdac inhibitors and hormone targeted drugs for the treatment of cancer | |
| EA200900203A1 (ru) | Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение | |
| MY199903A (en) | Combination therapy with controlled-release cnp agonists | |
| EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
| EA201391286A1 (ru) | Лечение солидных опухолей | |
| PL2288413T3 (pl) | Urządzenie terapeutyczne łączące radioterapię z termoterapią | |
| MX2019010732A (es) | Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| MX2020004960A (es) | Asociacion de activos para tratar el cancer de prostata. | |
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| WO2019118779A3 (en) | Peptides and other agents for treating pain and increasing pain sensitivity | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. | |
| PH12022551021A1 (en) | Sequential anti-cd19 therapy |